PTSD
MCID: PST028
MIFTS: 58

Post-Traumatic Stress Disorder (PTSD)

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Post-Traumatic Stress Disorder

MalaCards integrated aliases for Post-Traumatic Stress Disorder:

Name: Post-Traumatic Stress Disorder 12 29 42 15 17 71 32
Stress Disorders, Post-Traumatic 43
Post Traumatic Stress Disorder 74
Posttraumatic Stress Disorder 15
Traumatic Neurosis 12
Ptsd 47

Classifications:



External Ids:

Disease Ontology 12 DOID:2055
ICD9CM 34 309.81
MeSH 43 D013313
NCIt 49 C3389
SNOMED-CT 67 47505003
ICD10 32 F43.1
UMLS 71 C0038436

Summaries for Post-Traumatic Stress Disorder

MedlinePlus : 42 What is post-traumatic stress disorder (PTSD)? Post-traumatic stress disorder (PTSD) is a mental health disorder that some people develop after they experience or see a traumatic event. The traumatic event may be life-threatening, such as combat, a natural disaster, a car accident, or sexual assault. But sometimes the event is not necessarily a dangerous one. For example, the sudden, unexpected death of a loved one can also cause PTSD. It's normal to feel afraid during and after a traumatic situation. The fear triggers a "fight-or-flight" response. This is your body's way of helping to protect itself from possible harm. It causes changes in your body such as the release of certain hormones and increases in alertness, blood pressure, heart rate, and breathing. In time, most people recover from this naturally. But people with PTSD don't feel better. They feel stressed and frightened long after the trauma is over. In some cases, the PTSD symptoms may start later on. They might also come and go over time. What causes post-traumatic stress disorder (PTSD)? Researchers don't know why some people get PTSD and others don't. Genetics, neurobiology, risk factors, and personal factors may affect whether you get PTSD after a traumatic event. Who is at risk for post-traumatic stress disorder (PTSD)? You can develop PTSD at any age. Many risk factors play a part in whether you will develop PTSD. They include Your gender; women are more likely to develop PTSD Having had trauma in childhood Feeling horror, helplessness, or extreme fear Going through a traumatic event that lasts a long time Having little or no social support after the event Dealing with extra stress after the event, such as loss of a loved one, pain and injury, or loss of a job or home Having a history of mental illness or substance use What are the symptoms of post-traumatic stress disorder (PTSD)? There are four types of PTSD symptoms, but they may not be the same for everyone. Each person experiences symptoms in their own way. The types are Re-experiencing symptoms, where something reminds you of the trauma and you feel that fear again. Examples include Flashbacks, which cause you to feel like you are going through the event again Nightmares Frightening thoughts Avoidance symptoms, where you try to avoid situations or people that trigger memories of the traumatic event. This may cause you to Stay away from places, events, or objects that are reminders of the traumatic experience. For example, if you were in a car accident, you might stop driving. Avoiding thoughts or feelings related to the traumatic event. For example, you might try to stay very busy to try to avoid thinking about what happened. Arousal and reactivity symptoms, which may cause you to be jittery or be on the lookout for danger. They include Being easily startled Feeling tense or "on edge" Having difficulty sleeping Having angry outbursts Cognition and mood symptoms, which are negative changes in beliefs and feelings. They include Trouble remembering important things about the traumatic event Negative thoughts about yourself or the world Feeling blame and guilt No longer being interested in things you enjoyed Trouble concentrating The symptoms usually start soon after the traumatic event. But sometimes they may not appear until months or years later. They also may come and go over many years. If your symptoms last longer than four weeks, cause you great distress, or interfere with your work or home life, you might have PTSD. How is post-traumatic stress disorder (PTSD) diagnosed? A health care provider who has experience helping people with mental illnesses can diagnose PTSD. The provider will do a mental health screening and may also do a physical exam. To get a diagnosis of PTSD, you must have all of these symptoms for at least one month: At least one re-experiencing symptom At least one avoidance symptom At least two arousal and reactivity symptoms At least two cognition and mood symptoms What are the treatments for post-traumatic stress disorder (PTSD)? The main treatments for PTSD are talk therapy, medicines, or both. PTSD affects people differently, so a treatment that works for one person may not work for another. If you have PTSD, you need to work with a mental health professional to find the best treatment for your symptoms. Talk therapy, or psychotherapy, which can teach you about your symptoms. You will learn how to identify what triggers them and how to manage them. There are different types of talk therapy for PTSD. Medicines can help with the symptoms of PTSD. Antidepressants may help control symptoms such as sadness, worry, anger, and feeling numb inside. Other medicines can help with sleep problems and nightmares. Can post-traumatic stress disorder (PTSD) be prevented? There are certain factors that can help reduce the risk of developing PTSD. These are known as resilience factors, and they include Seeking out support from other people, such as friends, family, or a support group Learning to feel good about your actions in the face of danger Having a coping strategy or a way of getting through the bad event and learning from it Being able to act and respond effectively despite feeling fear Researchers are studying the importance of the resilience and risk factors for PTSD. They are also studying how genetics and neurobiology can affect the risk of PTSD. With more research, someday it may be possible to predict who is likely to develop PTSD. This could also help in finding ways to prevent it. NIH: National Institute of Mental Health

MalaCards based summary : Post-Traumatic Stress Disorder, also known as stress disorders, post-traumatic, is related to acute stress disorder and traumatic brain injury, and has symptoms including nervousness An important gene associated with Post-Traumatic Stress Disorder is LINC01090 (Long Intergenic Non-Protein Coding RNA 1090), and among its related pathways/superpathways are Parkinson disease and Circadian entrainment. The drugs Tramadol and Diazepam have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 An anxiety disorder which results from a traumatic experience that results in psychological trauma.

Wikipedia : 74 Posttraumatic stress disorder (PTSD)[note 1] is a mental disorder that can develop after a person is... more...

Related Diseases for Post-Traumatic Stress Disorder

Diseases related to Post-Traumatic Stress Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 508)
# Related Disease Score Top Affiliating Genes
1 acute stress disorder 33.9 SLC6A4 NR3C1 FKBP5 CRP CRH BDNF
2 traumatic brain injury 33.6 DRD2 COMT BDNF APOE
3 brain injury 32.1 DRD2 COMT BDNF APOE
4 depression 32.0 SLC6A4 MAOA HTR2A CRH BDNF
5 alcohol use disorder 31.7 SLC6A4 HTR2A DRD2 CRH COMT BDNF
6 neurotic disorder 31.5 SLC6A4 MAOA HTR2A BDNF
7 adjustment disorder 31.5 SLC6A4 HTR2A BDNF
8 amnestic disorder 31.5 PREP DRD2 CNR1 BDNF APOE
9 alexithymia 31.5 SLC6A4 DRD2 CRP COMT
10 somatization disorder 31.4 SLC6A4 HTR2A CRH
11 sexual disorder 31.4 SLC6A4 HTR2A DRD2
12 panic disorder 31.4 SLC6A4 MAOA HTR2A DRD2 CRH COMT
13 sleep apnea 31.3 SLC6A4 IL1B HTR2A CRP BDNF APOE
14 sleep disorder 31.3 SLC6A4 IL1B HTR2A DRD2 CRP BDNF
15 mental depression 31.3 SLC6A4 NR3C1 MAOA IL1B HTR2A FKBP5
16 substance abuse 31.3 SLC6A4 MAOA HTR2A DRD2 DBH CRH
17 social phobia 31.2 SLC6A4 MAOA DRD2 COMT BDNF
18 mood disorder 31.2 SLC6A4 NR3C1 MAOB MAOA HTR2A DRD2
19 borderline personality disorder 31.2 SLC6A4 NR3C1 MAOA HTR2A FKBP5 DRD2
20 personality disorder 31.2 SLC6A4 NR3C1 MAOB MAOA HTR2A FKBP5
21 postpartum depression 31.1 SLC6A4 NR3C1 MAOA CRH COMT BDNF
22 conduct disorder 31.1 SLC6A4 MAOA DRD2 DBH COMT
23 substance dependence 31.1 SLC6A4 MAOA DRD2 CRH COMT CNR1
24 dysthymic disorder 31.1 SLC6A4 MAOA HTR2A CRH BDNF
25 dementia 31.0 MAOB IL1B HTR2A DRD2 COMT BDNF
26 psychotic disorder 31.0 SLC6A4 MAOB MAOA HTR2A DRD2 DBH
27 pain agnosia 31.0 IL1B FAAH CNR1
28 dissociative disorder 31.0 SLC6A4 HTR2A BDNF
29 agoraphobia 31.0 SLC6A4 MAOA HTR2A CRH COMT BDNF
30 drug dependence 30.9 SLC6A4 DRD2 CRH CNR1 BDNF
31 heroin dependence 30.9 SLC6A4 MAOA DRD2 COMT BDNF
32 generalized anxiety disorder 30.9 SLC6A4 NR3C1 MAOA HTR2A DRD2 CRP
33 obsessive-compulsive personality disorder 30.9 SLC6A4 HTR2A COMT
34 opiate dependence 30.9 SLC6A4 DRD2 CRH CNR1
35 pure autonomic failure 30.9 MAOB MAOA DBH
36 fibromyalgia 30.9 SLC6A4 PREP IL1B HTR2A DRD2 CRP
37 antisocial personality disorder 30.8 SLC6A4 MAOB MAOA HTR2A DRD2 COMT
38 paine syndrome 30.8 IL1B COMT BDNF
39 eating disorder 30.8 SLC6A4 HTR2A FAAH DRD2 CRH COMT
40 bipolar i disorder 30.8 SLC6A4 HTR2A DRD2 COMT BDNF
41 chronic fatigue syndrome 30.8 SLC6A4 NR3C1 MAOA IL1B HTR2A CRH
42 cocaine dependence 30.8 SLC6A4 MAOB HTR2A DRD2 DBH COMT
43 myocardial infarction 30.8 SLC6A4 IL1B HTR2A CRP COMT CNR1
44 obsessive-compulsive disorder 30.8 SLC6A4 MAOB MAOA IL1B HTR2A FKBP5
45 vascular dementia 30.7 IL1B CRP APOE
46 hypochondriasis 30.7 SLC6A4 HTR2A BDNF
47 cannabis dependence 30.7 FAAH DRD2 COMT CNR1
48 attention deficit-hyperactivity disorder 30.7 SLC6A4 NR3C1 MAOB MAOA HTR2A FKBP5
49 cocaine abuse 30.7 SLC6A4 MAOB DRD2 DBH BDNF
50 alcohol dependence 30.7 SLC6A4 MAOB MAOA IL1B HTR2A FAAH

Comorbidity relations with Post-Traumatic Stress Disorder via Phenotypic Disease Network (PDN):


Anxiety Dysthymic Disorder
Major Depressive Disorder

Graphical network of the top 20 diseases related to Post-Traumatic Stress Disorder:



Diseases related to Post-Traumatic Stress Disorder

Symptoms & Phenotypes for Post-Traumatic Stress Disorder

UMLS symptoms related to Post-Traumatic Stress Disorder:


nervousness

MGI Mouse Phenotypes related to Post-Traumatic Stress Disorder:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.44 ADCYAP1 ADCYAP1R1 APOE BDNF CNR1 COMT
2 homeostasis/metabolism MP:0005376 10.41 ADCYAP1 ADCYAP1R1 APOE BDNF CNR1 COMT
3 nervous system MP:0003631 10.27 ADCYAP1 ADCYAP1R1 APOE BDNF CNR1 COMT
4 growth/size/body region MP:0005378 10.26 ADCYAP1 ADCYAP1R1 APOE BDNF CNR1 CRH
5 mortality/aging MP:0010768 10.22 ADCYAP1 ADCYAP1R1 APOE BDNF CNR1 DBH
6 endocrine/exocrine gland MP:0005379 10.15 APOE BDNF COMT CRH DBH DRD2
7 adipose tissue MP:0005375 10.13 ADCYAP1 APOE CNR1 CRH DBH DRD2
8 integument MP:0010771 10.13 APOE BDNF CNR1 CRH DBH DRD2
9 normal MP:0002873 9.96 ADCYAP1R1 BDNF CNR1 CRH DBH DRD2
10 no phenotypic analysis MP:0003012 9.92 ADCYAP1 ADCYAP1R1 APOE BDNF CNR1 CRH
11 renal/urinary system MP:0005367 9.76 APOE COMT CRH DRD2 FKBP5 MAOB
12 reproductive system MP:0005389 9.61 ADCYAP1 ADCYAP1R1 APOE BDNF CNR1 COMT
13 taste/olfaction MP:0005394 8.92 APOE BDNF CNR1 DRD2

Drugs & Therapeutics for Post-Traumatic Stress Disorder

Drugs for Post-Traumatic Stress Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 351)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
2
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
3
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
4
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
5
Vortioxetine Approved, Investigational Phase 4 508233-74-7 9966051
6
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
7
Cycloserine Approved Phase 4 68-41-7 401 6234
8
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
9
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
10
Doxazosin Approved Phase 4 74191-85-8 3157
11
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
12
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
13
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
14
Histamine Approved, Investigational Phase 4 51-45-6 774
15
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
16
Mianserin Approved, Investigational Phase 4 24219-97-4 4184
17
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
18
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
19
Haloperidol Approved Phase 4 52-86-8 3559
20
Asenapine Approved Phase 4 65576-45-6, 85650-56-2 3001386
21
Memantine Approved, Investigational Phase 4 19982-08-2 4054
22
Levodopa Approved Phase 4 59-92-7 6047
23
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
24
Pimavanserin Approved, Investigational Phase 4 706779-91-1 16058810
25
Promethazine Approved, Investigational Phase 4 60-87-7 4927
26
Suvorexant Approved, Investigational Phase 4 1030377-33-3
27
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
28
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
29
Carbon monoxide Approved, Investigational Phase 4 630-08-0 281
30
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
31
Citalopram Approved Phase 4 59729-33-8 2771
32
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
33
Prazosin Approved Phase 4 19216-56-9 4893
34
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
35
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
36
Sertraline Approved Phase 4 79617-96-2 68617
37
Propranolol Approved, Investigational Phase 4 525-66-6 4946
38
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
39
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
40
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
41
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
42 Olive Phase 4
43 Hormones Phase 4
44 Antineoplastic Agents, Hormonal Phase 4
45 Hormone Antagonists Phase 4
46 Quetiapine Fumarate Phase 4 111974-72-2
47 Serotonin 5-HT1 Receptor Agonists Phase 4
48 Serotonin 5-HT3 Receptor Antagonists Phase 4
49 Calcium, Dietary Phase 4
50 calcium channel blockers Phase 4

Interventional clinical trials:

(show top 50) (show all 1756)
# Name Status NCT ID Phase Drugs
1 A Prospective Double Blind Randomized Placebo Controlled Trial of Repetitive Transcranial Magnetic Stimulation for Posttraumatic Stress Disorder Unknown status NCT00134446 Phase 4
2 A Double-Blind, Placebo-Controlled, Flexible-Dose Pilot Clinical Trial of Once-Daily Extended-Release Tramadol for the Treatment of PTSD Unknown status NCT01517711 Phase 4 Tramadol;Placebo
3 The Effect of 21-Days Intranasal Oxytocin on Clinical Symptoms and Social Function in Patients With Post Traumatic Stress Disorder (PTSD), a Randomized Controled Trail Unknown status NCT02336568 Phase 4 Oxytoine;PLACEBO
4 Predictors of Treatment Response to Fluoxetine in PTSD Following a Recent History of War Zone Stress Exposure Unknown status NCT00633685 Phase 4 Fluoxetine;Placebo
5 A Randomized Cross Over Trial of Two Treatments for Obstructive Sleep Apnea in Veterans With Post Traumatic Stress Disorder Unknown status NCT01535586 Phase 4
6 Early Pharmacological Intervention With Diazepam in the Emergency Room Setting to Prevent Posttraumatic Stress Disorder (PTSD). Unknown status NCT01221883 Phase 4 Diazepam
7 Identifying Neural Mechanisms of PTSD Symptom Reduction Induced by Combined Estrogen and Prolonged Exposure Therapy Unknown status NCT03371654 Phase 4 Estradiol;Placebo
8 Suvorexant and Trauma Related Insomnia Unknown status NCT02704754 Phase 4 suvorexant
9 Double Blind, Placebo-Controlled Trial of THC as add-on Therapy for PTSD Unknown status NCT00965809 Phase 4 Tetrahydrocannabinol
10 A Placebo-controlled, Randomized, Double-blind Comparison of Placebo vs Short Course Low Dose Corticosteroids on Posttraumatic Stress Disorder (PTSD) Completed NCT00204737 Phase 4 prednisone;placebo
11 Neurofunctional Markers of SSRI Treatment Response in PTSD Completed NCT00700999 Phase 4 Paroxetine
12 Eszopiclone for the Treatment of PTSD Completed NCT01605253 Phase 4 Eszopiclone;Placebo
13 Evaluation of the Efficacy of Vortioxetine for Posttraumatic Stress Disorder Completed NCT02637895 Phase 4 Placebo;Vortioxetine
14 Prophylaxis of Posttraumatic Stress Disorder With Post-Trauma Propranolol Completed NCT00158262 Phase 4 Propranolol;Placebo
15 Randomized Trial of Sertraline, Prolonged Exposure, and Their Combination for Post-traumatic Stress Disorder (PTSD) in Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF). Completed NCT01524133 Phase 4 Sertraline
16 Naltrexone and Cognitive-Behavioral Therapy for Patients With Alcoholism and Post-Traumatic Stress Disorder Completed NCT00006489 Phase 4 Naltrexone;Placebo
17 Reducing Suicidal Ideation Through Treatment of Nightmares-PTSD Completed NCT02199652 Phase 4 Prazosin;Placebo
18 Geodon (Ziprasidone) for Posttraumatic Stress Disorder Completed NCT00208208 Phase 4 Ziprasidone
19 Combined Treatment With a Benzodiazepine (Clonazepam) and a Selective Serotonin Reuptake Inhibitor (Paroxetine) for Rapid Treatment of Posttraumatic Stress Disorder (PTSD) Completed NCT00025740 Phase 4 clonazepam and paroxetine
20 Risperidone Monotherapy in the Treatment of PTSD in Women Survivors of Domestic Abuse and Rape Trauma: a Double-Blind, Placebo Controlled, Randomized Clinical Trial Completed NCT00208182 Phase 4 Risperidone
21 Topiramate in the Treatment of Post Traumatic Stress Disorder (PTSD) Completed NCT00203463 Phase 4 topiramate
22 Effects of Escitalopram on Autonomic Reactivity in Post Traumatic Stress Disorder Among Veterans of Operation Enduring Freedom and Iraqi Freedom (OEF/OIF) Completed NCT01271244 Phase 4 Escitalopram
23 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Posttraumatic Stress Disorder in Civilians Completed NCT00208130 Phase 4 Topiramate
24 Coordinated Anxiety Learning and Management (CALM): Improving Primary Care Anxiety Outcomes Completed NCT00347269 Phase 4 Psychotropic medication optimization
25 Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder Completed NCT00120250 Phase 4 Eszopiclone
26 Developing Memory Reconsolidation Blockers as Novel PTSD Treatments Completed NCT01490697 Phase 4 Mifepristone;d-Cycloserine;Placebo-matching Mifepristone;Placebo-matching d-Cycloserine (DCS)
27 The Outcome of Treatment of Traumatised Refugees With Trauma-Focused Cognitive Behavioural Therapy and / or Antidepressants - a Randomised Controlled Trial Completed NCT00917397 Phase 4 Sertraline
28 Cognitive Behavioral Therapy vs. Sertraline in the Treatment of Post Traumatic Stress Disorder Completed NCT00391430 Phase 4 Sertraline
29 Telemedicine Outreach for Post Traumatic Stress in CBOCs Completed NCT00821678 Phase 4
30 Atomoxetine in Comorbid ADHD/PTSD: A Pilot, Placebo-Controlled Feasibility Study Completed NCT02287038 Phase 4 Atomoxetine 80 MG
31 The Effect of Intranasal Oxytocin on Emphatic Abilities in Patients With PTSD Completed NCT01325168 Phase 4 syntocinon nasal spray;placebo nasal spray
32 A Pilot Study to Assess the Effects of Doxazosin on Polysomnography in PTSD Completed NCT01959022 Phase 4 Doxazosin XL
33 A Double-blind, Placebo-controlled Randomized Trial of Vilazodone in the Treatment of Posttraumatic Stress Disorder Completed NCT01715519 Phase 4 Treatment (Viibryd)
34 The Treatment of Traumatised Refugees With Sertraline Versus Venlafaxine in Combination With Psychotherapy - a Randomised Clinical Study Completed NCT01569685 Phase 4 Venlafaxine;Sertraline
35 Combined Mirtazapine and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment of Post-traumatic Stress Disorder (PTSD) Completed NCT01178671 Phase 4 Mirtazapine;Sertraline
36 Treatment of Sleep Disturbances in Trauma-affected Refugees: A Randomised Controlled Trial Completed NCT02761161 Phase 4 Mianserin
37 Efficacy of an SSRI in Acute Stress Disorder and PTSD Completed NCT00050804 Phase 4 sertraline
38 Effects of THC on Retention of Memory for Fear Extinction Learning in PTSD: R61 Study Completed NCT03008005 Phase 4 Placebo Oral Capsule;Dronabinol Cap 5 milligrams (MG);Dronabinol Cap 10 milligrams (MG)
39 Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy Completed NCT01087736 Phase 4 Topiramate
40 Minocycline for Treatment of Posttraumatic Stress Disorder in Veterans Completed NCT03340350 Phase 4 Minocycline
41 Interest for a Relative of Seeing Himself Proposing to Witness Resuscitation of a Family Member Victim of a Cardiac Arrest Completed NCT01009606 Phase 4
42 Treatment for Psychogenic Nonepileptic Seizures: A Pilot, 12 Week, Prospective, Randomized, Placebo-controlled, Double-blind, Clinical Trial of Sertraline in the Treatment of Comorbid Psychiatric Disorders in NES Completed NCT00159965 Phase 4 sertraline;placebo
43 Preventing Post-Operative Delirium in Pneumonectomy, Esophagectomy and Thoracotomy Patients Completed NCT02213900 Phase 4 Haloperidol;Placebo
44 An Open Label Pilot Study of Adjunctive Asenapine for the Treatment of Posttraumatic Stress Disorder Completed NCT01587118 Phase 4 Adjunctive asenapine
45 Secondary Prevention With Paroxetine vs. Placebo in Subthreshold Posttraumatic Stress Disorder (PTSD) Completed NCT00560612 Phase 4 Paroxetine;Placebo
46 A Controlled Trial of Topiramate Treatment for Alcohol Dependence in Veterans With PTSD Completed NCT01749215 Phase 4 Topiramate;placebo
47 An Open-Label Trial of Memantine for Cognitive Impairment in Patients With Post-Traumatic Stress Disorder Completed NCT02258828 Phase 4 Memantine;Placebo
48 Effects of Hydrocortisone and D-Cycloserine on Fear Extinction in Veterans With Posttraumatic Stress Disorder Completed NCT00674570 Phase 4 Hydrocortisone;D-Cycloserine;Placebo
49 Combination Treatment for PTSD After the WTC Attack Completed NCT01130103 Phase 4 Paroxetine
50 Neural Circuits in Women With Abuse and Posttraumatic Stress Disorder Completed NCT01681849 Phase 4 Placebo;Paroxetine

Search NIH Clinical Center for Post-Traumatic Stress Disorder

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carbamazepine
Lithium
Lithium Aspartate
Lithium Carbonate
lithium citrate
nefazodone
Paroxetine
Paroxetine Hydrochloride
Sertraline
Sertraline Hydrochloride
Tranylcypromine
Tranylcypromine sulfate

Cochrane evidence based reviews: stress disorders, post-traumatic

Genetic Tests for Post-Traumatic Stress Disorder

Genetic tests related to Post-Traumatic Stress Disorder:

# Genetic test Affiliating Genes
1 Post-Traumatic Stress Disorder 29

Anatomical Context for Post-Traumatic Stress Disorder

MalaCards organs/tissues related to Post-Traumatic Stress Disorder:

40
Brain, Eye, Testes, Amygdala, Heart, Cortex, Prefrontal Cortex

Publications for Post-Traumatic Stress Disorder

Articles related to Post-Traumatic Stress Disorder:

(show top 50) (show all 11002)
# Title Authors PMID Year
1
Effectiveness and safety of ear acupuncture for trauma-related mental disorders after large-scale disasters: A PRISMA-compliant systematic review. 61 42
32080154 2020
2
Medical Surgical Nurse Self-perceived Competency in Posttraumatic Stress Disorder/Substance Use Disorder Veteran Care in a Non-Veterans Health Administration Setting. 42
32195913 2020
3
The effects of psychotherapy for depressed or posttraumatic stress disorder women with childhood sexual abuse history: Meta-analysis of randomized controlled trials. 42
32332620 2020
4
The D2 dopamine receptor gene variant C957T affects human fear conditioning and aversive priming. 54 61
19900188 2010
5
Candidate-gene approach in fibromyalgia syndrome: association analysis of the genes encoding substance P receptor, dopamine transporter and alpha1-antitrypsin. 54 61
20074437 2009
6
The DRD2 gene 957C>T polymorphism is associated with posttraumatic stress disorder in war veterans. 54 61
18833581 2009
7
Association of the cannabinoid receptor gene (CNR1) with ADHD and post-traumatic stress disorder. 61 54
18213623 2008
8
Effects of trauma-related audiovisual stimulation on cerebrospinal fluid norepinephrine and corticotropin-releasing hormone concentrations in post-traumatic stress disorder. 61 54
18295412 2008
9
Glucocorticoid receptor activation is involved in producing abnormal phenotypes of single-prolonged stress rats: a putative post-traumatic stress disorder model. 61 54
17644267 2007
10
No association between the Clara cell secretory protein (CC16) gene polymorphism and personality traits. 54 61
16764982 2006
11
The D2 dopamine receptor (DRD2) gene is associated with co-morbid depression, anxiety and social dysfunction in untreated veterans with post-traumatic stress disorder. 61 54
16632165 2006
12
Expression of c-fos and BDNF mRNA in subregions of the prefrontal cortex of male and female rats after acute uncontrollable stress. 54 61
15993862 2005
13
Glucocorticoid receptor polymorphisms and post-traumatic stress disorder. 61 54
15511603 2005
14
Neurobiological characteristics of rhesus macaque abusive mothers and their relation to social and maternal behavior. 54 61
15652254 2005
15
An increased capacity for adrenal DHEA release is associated with decreased avoidance and negative mood symptoms in women with PTSD. 61 54
15199367 2004
16
Effect of topiramate on glucocorticoid receptor mediated action. 54 61
14666121 2004
17
The effects of chronic treatment with the mood stabilizers valproic acid and lithium on corticotropin-releasing factor neuronal systems. 61 54
12606697 2003
18
Cerebrospinal fluid corticotropin-releasing factor (CRF) and vasopressin concentrations predict pituitary response in the CRF stimulation test: a multiple regression analysis. 61 54
12629539 2003
19
Flow cytometric determination of glucocorticoid receptor (GCR) expression in lymphocyte subpopulations: lower quantity of GCR in patients with post-traumatic stress disorder (PTSD). 61 54
12562397 2003
20
Harmful drinking in military veterans with post-traumatic stress disorder: association with the D2 dopamine receptor A1 allele. 54 61
12217937 2002
21
Corticotropin-releasing hormone in depression and post-traumatic stress disorder. 54 61
11337099 2001
22
The DRD2 gene in psychiatric and neurological disorders and its phenotypes. 61 54
11256581 2000
23
Plasma neuropeptide Y (NPY) increases in humans in response to the alpha 2 antagonist yohimbine. 54 61
9608581 1998
24
Effects of psychological stress on serum prolyl endopeptidase and dipeptidyl peptidase IV activity in humans: higher serum prolyl endopeptidase activity is related to stress-induced anxiety. 54 61
9802123 1998
25
An open trial of moclobemide in the treatment of post-traumatic stress disorder. 61 54
9347385 1997
26
Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. 61 54
9137116 1997
27
Persistent changes in corticotropin-releasing factor systems due to early life stress: relationship to the pathophysiology of major depression and post-traumatic stress disorder. 54 61
9230630 1997
28
Hypersensitivity of the hypothalamic-pituitary-adrenal axis to naloxone in post-traumatic stress disorder. 54 61
8392385 1993
29
Brain-wide mapping of c-fos expression in the single prolonged stress model and the effects of pretreatment with ACH-000029 or prazosin. 61
32478146 2020
30
Social support modulates the association between PTSD diagnosis and medial frontal volume in Chinese adults who lost their only child. 61
32490056 2020
31
Repeated exposure of naïve and peripheral nerve-injured mice to a snake as an experimental model of post-traumatic stress disorder and its co-morbidity with neuropathic pain. 61
32474017 2020
32
Lower levels of bodily pain increase risk for non-medical use of prescription drugs among current US reserve soldiers. 61
32315933 2020
33
Riemannian classifier enhances the accuracy of machine-learning-based diagnosis of PTSD using resting EEG. 61
32376342 2020
34
Registered clinical trials investigating ketamine for psychiatric disorders. 61
32315806 2020
35
TLR4/MyD88/NF-κB-Mediated Inflammation Contributes to Cardiac Dysfunction in Rats of PTSD. 61
31939007 2020
36
The Effectiveness of Using Neurofeedback in the Treatment of Post-Traumatic Stress Disorder: A Systematic Review. 61
29890906 2020
37
Stress-induced blood brain barrier disruption: Molecular mechanisms and signaling pathways. 61
32275963 2020
38
Polyvictimization and mental health consequences of female genital mutilation/circumcision (FGM/C) among Somali refugees in Kenya. 61
31711407 2020
39
The Association Between Sexual Functioning and Suicide Risk in U.S. Military Veteran Couples Seeking Treatment for Post-Traumatic Stress Disorder. 61
31915971 2020
40
Post-Traumatic Stress Disorder is Associated with further Increased Parkinson's Disease Risk in Veterans with Traumatic Brain Injury. 61
32232880 2020
41
Increased Vascular Pathology in Older Veterans With a Purple Heart Commendation or Chronic Post-Traumatic Stress Disorder. 61
31426715 2020
42
The Role of Medical Specialization on Posttraumatic Symptoms in Pediatric Nurses. 61
32339973 2020
43
Ginsenoside Rg1 fails to rescue PTSD-like behaviors in a mice model of single-prolonged stress. 61
32482388 2020
44
Prevalence and correlates of comorbid PTSD with depression among older people exposed to the Jeju April 3 incident. 61
32379624 2020
45
Self-concept, post-traumatic self-appraisals and post-traumatic psychological adjustment: what are the relationships? 61
32301403 2020
46
Patient-related stressful situations and stress-related outcomes in emergency nurses: A cross-sectional study on the role of work factors and recovery during leisure time. 61
32446016 2020
47
Cannabinoids as therapeutics for PTSD. 61
32311373 2020
48
Delayed behavioral and genomic responses to acute combined stress in zebrafish, potentially relevant to PTSD and other stress-related disorders: Focus on neuroglia, neuroinflammation, apoptosis and epigenetic modulation. 61
32344037 2020
49
Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study. 61
31745697 2020
50
High and low anxiety phenotypes in a rat model of complex post-traumatic stress disorder are associated with different alterations in regional brain monoamine neurotransmission. 61
32361171 2020

Variations for Post-Traumatic Stress Disorder

Expression for Post-Traumatic Stress Disorder

Search GEO for disease gene expression data for Post-Traumatic Stress Disorder.

Pathways for Post-Traumatic Stress Disorder

Pathways related to Post-Traumatic Stress Disorder according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.01 MAOB MAOA IL1B DRD2 BDNF APOE
2
Show member pathways
12.61 MAOB MAOA DRD2 COMT ADCYAP1R1 ADCYAP1
3 12.17 DRD2 BDNF ADCYAP1R1 ADCYAP1
4
Show member pathways
11.88 MAOB MAOA DRD2 BDNF
5 11.86 SLC6A4 MAOB MAOA HTR2A
6 11.77 SLC6A4 NR3C1 MAOA IL1B HTR2A BDNF
7
Show member pathways
11.55 MAOB MAOA DBH COMT
8 11.35 NR3C1 IL1B APOE
9 11.1 SLC6A4 MAOA HTR2A
10
Show member pathways
11.09 SLC6A4 MAOA IL1B DBH
11
Show member pathways
11.01 SLC6A4 MAOA COMT
12
Show member pathways
10.92 MAOA DBH COMT
13
Show member pathways
10.7 MAOB MAOA COMT
14
Show member pathways
10.67 MAOB MAOA
15
Show member pathways
10.59 ADCYAP1R1 ADCYAP1
16 10.58 MAOB MAOA COMT
17
Show member pathways
10.46 SLC6A4 MAOB MAOA DRD2 DBH COMT

GO Terms for Post-Traumatic Stress Disorder

Cellular components related to Post-Traumatic Stress Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.73 SLC6A4 HTR2A DRD2 DBH CRH CNR1
2 dendrite GO:0030425 9.72 HTR2A DRD2 COMT BDNF APOE
3 axon GO:0030424 9.55 HTR2A DRD2 COMT CNR1 BDNF
4 integral component of postsynaptic membrane GO:0099055 9.13 SLC6A4 HTR2A DRD2
5 integral component of presynaptic membrane GO:0099056 8.92 SLC6A4 HTR2A DRD2 CNR1

Biological processes related to Post-Traumatic Stress Disorder according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.13 HTR2A DRD2 CRH CNR1 APOE ADCYAP1R1
2 positive regulation of gene expression GO:0010628 10.02 SLC6A4 IL1B CRP CRH ADCYAP1
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.9 HTR2A DRD2 APOE ADCYAP1
4 response to lipopolysaccharide GO:0032496 9.87 MAOB IL1B COMT CNR1
5 response to toxic substance GO:0009636 9.82 SLC6A4 MAOB DRD2
6 female pregnancy GO:0007565 9.81 CRH COMT ADCYAP1
7 positive regulation of neuron projection development GO:0010976 9.8 CNR1 BDNF APOE ADCYAP1
8 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.78 DRD2 CNR1 ADCYAP1R1
9 learning or memory GO:0007611 9.77 CRH CNR1 BDNF
10 sensory perception of pain GO:0019233 9.75 HTR2A CNR1 ADCYAP1
11 response to cocaine GO:0042220 9.71 DRD2 CRH CNR1
12 negative regulation of cell death GO:0060548 9.71 DRD2 CRH BDNF ADCYAP1R1
13 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.66 HTR2A DRD2
14 behavioral response to ethanol GO:0048149 9.65 DRD2 DBH
15 dopamine metabolic process GO:0042417 9.65 DRD2 COMT
16 regulation of synaptic transmission, GABAergic GO:0032228 9.65 DRD2 CNR1
17 associative learning GO:0008306 9.65 DRD2 DBH CRH
18 memory GO:0007613 9.65 SLC6A4 HTR2A DBH CNR1 BDNF
19 locomotory exploration behavior GO:0035641 9.63 CRH APOE
20 catecholamine metabolic process GO:0006584 9.63 MAOA COMT
21 activation of phospholipase C activity GO:0007202 9.63 HTR2A BDNF ADCYAP1R1
22 response to ethanol GO:0045471 9.63 MAOB DRD2 CRH CNR1 ADCYAP1R1 ADCYAP1
23 positive regulation of growth hormone secretion GO:0060124 9.62 DRD2 ADCYAP1
24 negative regulation of potassium ion transport GO:0043267 9.61 HTR2A ADCYAP1
25 response to pain GO:0048265 9.61 DBH CRH COMT
26 positive regulation of fever generation GO:0031622 9.56 IL1B CNR1
27 negative regulation of serotonin secretion GO:0014063 9.55 MAOB CNR1
28 positive regulation of cAMP-mediated signaling GO:0043950 9.54 CRH ADCYAP1R1 ADCYAP1
29 fear response GO:0042596 9.52 DBH BDNF
30 negative regulation of dopamine secretion GO:0033602 9.51 DRD2 CNR1
31 neurotransmitter catabolic process GO:0042135 9.5 MAOB MAOA COMT
32 dopamine catabolic process GO:0042420 9.26 MAOB MAOA DBH COMT
33 response to drug GO:0042493 9.23 SLC6A4 MAOB HTR2A DRD2 CRH COMT

Molecular functions related to Post-Traumatic Stress Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.11 SLC6A4 PREP NR3C1 MAOB MAOA IL1B
2 identical protein binding GO:0042802 9.91 SLC6A4 MAOB HTR2A DRD2 CRP CNR1
3 drug binding GO:0008144 9.43 HTR2A DRD2 CNR1
4 signaling receptor binding GO:0005102 9.35 DRD2 CRH BDNF APOE ADCYAP1
5 serotonin binding GO:0051378 9.32 SLC6A4 HTR2A
6 primary amine oxidase activity GO:0008131 8.62 MAOB MAOA

Sources for Post-Traumatic Stress Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....